Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 19/20 | 0.85 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.84 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.84 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.84 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.84 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14896646 | 0.93 | GABRA5 (0.87) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL4155478 | 0.92 | GABRA5 (1.00) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| Basmisanil SCHEMBL2685527 | 0.91 | GABRA5 (1.00) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2959565 | 0.91 | GABRA5 (0.84) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2927056 | 0.91 | GABRA5 (1.00) | GABRA5 | |
| SCHEMBL2928778 | 0.91 | GABRA5 (1.00) | GABRA5 | |
| Basmisanil SCHEMBL15064600 | 0.90 | GABRA5 (0.98) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL4162143 | 0.90 | GABRA5 (1.00) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL4154571 | 0.90 | GABRA5 (1.00) | GABRA5GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2923738 | 0.90 | GABRA5 (1.00) | GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2767536-B1 | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2015-09-02 | — | — | EP | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2227467-B1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8877783-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877782-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-11-04 | — | — | US | disclosed |
| US-8846719-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2767536-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20130281690-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130274468-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274469-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-10-17 | — | — | US | disclosed |
| US-8518974-B2 | Isoxazolo-pyridine derivatives | Hoffmann-La Roche Inc (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120184538-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-07-19 | — | — | US | disclosed |
| EP-2227467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009071476-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | GABRA5 1/4885GABRA1 2/4885GABRG2 21/4885 |
| US-20130274468-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885GABRA1 2/4885GABRG2 21/4885 |
| US-20130274467-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885GABRA1 2/4885GABRG2 21/4885 |
| US-20130281690-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885GABRA1 2/4885GABRG2 21/4885 |
| US-20130274469-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885GABRA1 2/4885GABRG2 21/4885 |
| US-20120184538-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | GABRA5, GABRA1, GABRA4 | GABRA5 1/4885GABRA1 2/4885GABRG2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.